- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Calcipotriol plus 5-FU better than 5-FU plus petroleum jelly for actinic keratosis treatment: Study
USA: In a new study, it was found that when compared to Topical 5-Fluorouracil (5-FU) plus petroleum jelly, calcipotriol with 5-FU reduced the quantity of actinic keratosis (AK) in the treated region (25 cm2) more, however, only 27% of individuals achieved total clearing on the face at week-8. Over a three-year period, calcipotriol + 5-FU reduced the risk of cutaneous squamous cell carcinoma (cSCC) on the face and scalp.
This study was conducted by Lindsey Mohney, Wake Forest School of Medicine, Winston-Salem, NC, and the team. The findings of this work were published in the Journal of Drugs in Dermatology
AK is a precancerous lesion that can lead to cSCC. 5-FU and imiquimod have been utilized for field-directed therapy for AK, but their usage has been limited due to unpleasant skin responses and extensive treatment periods. Therefore, the objective of this study was to evaluate existing evidence on the efficacy, tolerability, and long-term efficacy of a topical calcipotriol + 5-FU combination for field-directed AK treatment. A critical appraisal of the existing evidence was included in the systematic review.
For this study, in August 2021, a systematic review of the literature was conducted utilizing the EMBASE and MEDLINE databases. There were studies that looked at the use of calcipotriol and 5-FU to treat actinic keratosis (AK) and prevent cSCC.
The results of this study stated as follow:
1. Four studies satisfied the inclusion criteria in total. Three papers were included in the final analysis.
2. One clinical trial looked at the effectiveness of calcipotriol + 5-FU in the treatment of AK.
3. Another clinical experiment looked at the long-term efficacy of calcipotriol + 5-FU on cSCC prevention.
4. Retrospective research looked at the usage of calcipotriol and 5-FU in conjunction with cryotherapy.
When calcipotriol was added to 5-FU for the treatment of AK, it enhanced lesion clearance but decreased tolerability. More controlled investigations are needed concluded the Authors.
Reference:
Mohney L, Singh R, Grada A, Feldman S. Use of Topical Calcipotriol Plus 5-Fluorouracil in the Treatment of Actinic Keratosis: A Systematic Review. J Drugs Dermatol. 2022 Jan 1;21(1):60-65. doi:10.36849/JDD.2022.6632.
Medical Dialogues consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers. Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in.
Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: drkohli@medicaldialogues.in. Contact no. 011-43720751